The recipe behind this is prioritised brands with speed. Kisqali, Kesimpta, Pluvicto and Scemblix are growing rapidly, while Cosentyx continues to deliver reliably. In the fourth quarter, generics and US adjustments to revenue reductions slowed sales slightly, but Novartis remained stable in operational terms. At the same time, there was movement in the innovation story. A marketing authorisation application was submitted to the FDA for remibrutinib, Pluvicto is to move into an earlier line of therapy and pelabresib delivered encouraging phase III data. In addition, approvals for Itivosma in the USA and an extended EU authorisation for Scemblix have been granted.
Shareholders should benefit from this momentum. The Board of Directors proposed a dividend of 3.70 Swiss francs. Novartis expects sales growth in the low single-digit range for 2026 and a slight decline in core operating profit. This may sound defensive, but is above all a signal of discipline in a year of major patent expiries.
Press release from "Novartis AG" dated 4 February 2026